FDA approves first targeted leukemia drug for certain patients, plus 2 moreLate last week, FDA approved a new drug to treat acute myeloid leukemia (AML), the first treatment for Batten disease, and expanded the use of a current drug to treat liver cancer.
Family history, genetics play growing role in leukemia screeningInherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.
Novel immunotherapies for leukemia could raise life-threatening syndromeNovel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
How to identify ocular cancerOptometrists in a practice unaffiliated with a tertiary care center will rarely see patients ocular cancer, a disease that is both sight threatening and life threatening. Because it’s impossible to predict who will walk through your door, it’s necessary to remain vigilant for signs of ocular melanoma, basal cell carcinoma, ocular lymphoma and leukemia, as well as cancers that have metastasized to the eye.
New leukemia drug availableFDA recently approved venetoclax (Venclexta, AbbVie and Genentech) to treat chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least 1 prior therapy
Leukemia drug gets US okay, struggles in UKWhile FDA recently approved ibrutinib (Imbruvica, Janssen Biotech, Inc. and Pharmacyclics LLC) to treat patients with chronic lymphocytic leukemia (CLL), United Kingdom’s National Institute of Health and Care Excellence (NICE) will not yet recommend the medication.
Personalized strategies critical for childhood cancerNext-generation gene sequencing and other advanced technologies for personalized medicine may soon identify biomarkers that will improve treatment response and long-term toxicity risks for childhood cancer patients.
Midostaurin extends survival among some AML patients: StudyAML’s genetic complexity raises concerns about long-term prospects of single mutation-targeting agents
Cancer drug makers overcharge 600 timesPharmaceutical companies are charging up to 600 times what certain cancer drugs cost to make, and Americans are paying more than double the price charged in Europe for the tyrosine kinase inhibitors (TKIs).